Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11441 

26 5 U.S.C. 552(b)(8). 

27 5 U.S.C. 552(b)(4). 

28Note that the Board may disclose a summary 

of the results of supervisory stress testing pursuant 

to 12 CFR 225.8(h)(5)(iii) and publishes a summary 

of the results of stress testing pursuant to 12 CFR 

252.46(b) and 12 CFR 238.134, which includes 

aggregate data. In addition, under the Board’s 

regulations, covered companies must also publicly 

disclose a summary of the results of stress testing. 

See 12 CFR 252.58; 12 CFR 238.146. The public 

disclosure requirement contained in 12 CFR 252.58 

for covered BHCs and covered IHCs is separately 

accounted for by the Board in the Paperwork 

Reduction Act clearance for FR YY (OMB No. 7100– 

0350) and the public disclosure requirement for 

covered SLHCs is separately accounted for in by the 

Board in the Paperwork Reduction Act clearance for 

FR LL (OMB No. 7100–0380). 

process.26 In addition, confidential 

commercial or financial information, 

which a submitter both customarily and 

actually treats as private, may be exempt 

from disclosure under exemption 4 of 

the FOIA.27 28

Board of Governors of the Federal Reserve 

System, February 23, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–04194 Filed 2–28–22; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[30Day–22–0048] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Agency for 

Toxic Substances and Disease Registry 

(ATSDR) has submitted the information 

collection request titled ‘‘ATSDR 

Exposure Investigations (EIs)’’ to the 

Office of Management and Budget 

(OMB) for review and approval. ATSDR 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on August 13, 2021 to obtain 

comments from the public and affected 

agencies. ATSDR did not receive 

comments related to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

ATSDR will accept all comments for 

this proposed information collection 

project. The Office of Management and 

Budget is particularly interested in 

comments that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

ATSDR Exposure Investigations (EIs) 

(OMB Control No. 0923–0048, Exp. 04/ 

30/2022)—Extension—Agency for Toxic 

Substances and Disease Registry 

(ATSDR). 

Background and Brief Description 

The Agency for Toxic Substances and 

Disease Registry (ATSDR) is requesting 

a three-year extension of ‘‘ATSDR 

Exposure Investigations (EIs)’’ (OMB 

Control No. 0923–0048, Exp. 04/30/ 

2022). This generic clearance allows the 

agency to conduct EIs, through methods 

developed by ATSDR. After a chemical 

release or suspected release into the 

environment, EIs are usually requested 

by officials of a state health agency, 

county health departments, the 

Environmental Protection Agency 

(EPA), the general public, and ATSDR 

staff. EI results are used by public health 

professionals, environmental risk 

managers, and other decision makers to 

determine if current conditions warrant 

intervention strategies to minimize or 

eliminate human exposure. 

During the past three years, no EIs 

were completed. Instead, the ATSDR 

Office of Community Health and Hazard 

Assessment (OCHHA), using EI 

methods, completed eight Per- or 

Polyfluoroalkyl Substances Exposure 

Assessments (PFAS EAs) (OMB Control 

No. 0923–0059, Exp. 06/30/2022) at 

communities near U.S. military 

installations that used Aqueous Film 

Forming Foam (AFFF). The PFAS from 

the AFFF entered groundwater and 

impacted the drinking water in the 

nearby communities. In 2022, however, 

ATSDR is conducting a follow-up EI 

under this generic clearance ICR to 

supplement the PFAS EAs. This EI 

generic information collection (GenIC) 

will evaluate additional non-drinking 

water sources of environmental PFAS 

exposure in two of the former EA 

communities. 

The general EI methods are further 

described below. All of ATSDR’s 

targeted biological assessments (e.g., 

urine, blood) and some of the 

environmental investigations (e.g., air, 

water, soil, or food sampling) involve 

participants to determine whether they 

are or have been exposed to unusual 

levels of pollutants at specific locations 

(e.g., where people live, spend leisure 

time, or anywhere they might come into 

contact with contaminants under 

investigation). 

Questionnaires, appropriate to the 

specific contaminant, are generally 

needed in about half of the EIs (at most, 

approximately 12 per year) to assist in 

interpreting the biological or 

environmental sampling results. ATSDR 

collects contact information (e.g., name, 

address, phone number) to provide the 

participant with their individual results. 

ATSDR also collects information on 

other possible confounding sources of 

chemical(s) exposure such as medicines 

taken, foods eaten, hobbies, jobs, etc. In 

addition, ATSDR asks questions on 

recreational or occupational activities 

that could increase a participant’s 

exposure potential. That information 

represents an individual’s exposure 

history. 

The number of questions can vary 

depending on the number of chemicals 

being investigated, the route of exposure 

(e.g., breathing, eating, touching), and 

number of other sources of the 

chemical(s) (e.g., products used, jobs). 

We use approximately 12–20 questions 

about the pertinent environmental 

exposures per investigation. Typically, 

the number of participants in an 

individual EI ranges from 10 to 100. 

Participation is completely voluntary, 

and there are no costs to participants 


jspears on DSK121TN23PROD with NOTICES1
11442 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

other than their time. Based on a 

maximum of 12 EIs per year and 100 

participants each, the total estimated 

annualized burden hours are 600. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

per response 

(in hours) 

Exposure Investigation Participants ................ Chemical Exposure Questions ....................... 1,200 1 30/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04189 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–0010; Docket No. CDC–2022– 

0030] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Birth Defects Study To Evaluate 

Pregnancy exposureS (BD–STEPS). Data 

from BD–STEPS will play an important 

part in the decision-making process that 

determines federal research agendas, 

birth defect prevention activities, and 

the direction of funding programs such 

as cooperative agreements. 

DATES: CDC must receive written 

comments on or before May 2, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0030 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Birth Defects Study to Evaluate 

Pregnancy exposureS (BD–STEPS) 

(OMB Control No. 0920–0010, Exp. 2/ 

28/2023)—Extension—National Center 

on Birth Defects and Developmental 

Disabilities (NCBDDD), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Birth defects are associated with 

substantial morbidity and mortality in 

the United States. About one in every 33 

babies is born with a birth defect. Birth 

defects contributed to more than one 

million hospital stays in the U.S. in 

2013, resulting in $22.9 billion in 

hospital costs. Birth defects are the 

leading cause of infant mortality and the 

fifth leading cause of loss of potential 

years of life before age 65. One in five 

infant deaths is due to birth defects. 

For most birth defects, the causes are 

not known, making prevention efforts 

challenging to develop. However, to 

date, primary preventive measures are 

available for only a few birth defects. 

For example, vaccination programs have 

reduced the incidence of congenital 

rubella syndrome, Rh hemolytic disease 

of the newborn can be prevented by 

appropriate medical practices, and 

genetic counseling can provide parents 

with information about the increased 

risk of Down syndrome associated with 

advanced maternal age. Perhaps most 

importantly, folic acid intake before and 

during pregnancy can prevent many 

cases of fatal or permanently disabling 

neural tube defects such as anencephaly 

and spina bifida. 

This continued burden justifies 

reasonable attempts to reduce the 


jspears on DSK121TN23PROD with NOTICES1